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Abstract 
 
Nanoparticle carriers for delivery of anticancer agents enjoys its own unique place 
due to its stealth nature to body immune system. TiO2 nanoparticles remain intact in the 
intercellular and intracellular areas of the cell for clear detection instead of getting digested 
by the cell. Synthesis of nanocrystalline anatase TiO2 powders was done by high temperature 
hydrolysis of TiOSO4 aqueous solution. Morphological characterizations of particle size and 
shape which are the key features that govern the physical stability of TiO2 nanoparticles were 
studied by DLS, NTA, TEM and XRD. Crystalline purity was determined through FT-IR and 
zeta potential investigation verifies high stability of the nanoparticles.  
PCT is conjugated with the TiO2 nanoparticles because of its favourable mechanism 
of action in causing dynamic instability during the cell division process of the cancer cells 
resulting in apoptosis. The efficacy of PCT-TiO2 nanocomposites is studied on MCF 7 breast 
cancer cell line.  
Drug encapsulation and drug release profile has been performed in vitro at three 
different pH. The quantitative estimation of amount of drug release, verified through HPLC 
shows maximum release of 87.197 µg at pH 5.2, 70.023 µg at pH 6.0 and minimum release 
of 20.341 µg at pH 7.4. This is the most significant outcome in the study for which the pH 
sensitive PCT-TiO2 nanocomposite can be claimed as a smart nanocarrier.  
To establish the probable mechanism of this TiO2 nanoparticulate carrier system, a 
proposed model system is given which is based on the difference in the value of the 
complexation constant in order of 1 for TiO2 at pH below 6.7 and above it. Furthermore the 
stability of this complex and its dissociation is also affected by concentration of Ca
2+
 and 
capacitance of plasma membrane of normal cell and cancerous cell. 
Thereafter a number of biological study has been performed to verify the cellular 
uptake rate, cytotoxicity, type of death associated with cancerous cells of breast cancer cell 
line MCF-7. The flow cytometry confirms that the cellular uptake follow a time dependent 
pattern since there is increase in fluorescence intensity with respect to time up to 24 hours, 
establishing the fact that accumulation of nanoparticles inside the cells occurs gradually with 
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time. The MTT assay show synergistic effect of TiO2-PCT nanocomposite than that of pure 
PCT over MCF-7 cell line. This study is further supported by the fluorescent pictures of 
apoptotic cells containing fragmented nucleus and DNA using 4′, 6-diamidino-2-
phenylindole staining. Thus there is a possibility of existence of two types of cell death 
pathway: one is apoptosis dependent and the other normal PCT induced microtubule 
stabilized cell killing.  
It was demonstrated that PCT-TiO2 nanocomposite increases intracellular 
concentration of PCT and enhance its anticancer efficiency by inducing the above two 
mechanism and hence acts as an efficient DDS importing PCT into target cancer cells. These 
findings suggest that “smart” PCT delivery strategy is a promising approach to cancer 
therapy.  
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1 
INTRODUCTION 
 
The high surface energy of nanoparticles permits them to accommodate higher 
quantity of drug molecules and their small size is advantageous for attaching to multivalent 
targeting ligands. Once the nanoparticles are attached to the cell it is prelude to uptake 
because of their relative lack of shear stress. Their ability to bypass the drug resistance 
mechanism makes it a valuable aid in drug delivery system in an effort to increase the 
bioavailability of drugs at the intended site of action
1
.  
Study was conducted on TiO2 nanoparticles as they are pH sensitive, show a 
significant tolerance level and have high affinity towards phosphate moieties. TiO2 exists in 
three types of phases i.e. rutile, anatase and brookite. The metastable anatase and brookite 
transform to stable rutile upon heating. Brookite is orthorhombic while the other two phases 
are tetragonal in shape
2
. Nanosized anatase TiO2 has large effective surface area that 
enhances the surface reactions
3
. Titania nanoparticles can be synthesised by various different 
methods like metal organic chemical vapour deposition, oxidation of TiCl4, sulfate process, 
chloride process, impregnation, coprecipitation, industrial preparation by plasma spray 
synthesis, hydrothermal process and sol-gel route. In this study the high temperature 
hydrolysis of TiOSO4 aqueous solution is adopted to synthesis nanocrystalline anatase TiO2 
powders. In order to ensure its physicochemical properties for drug loading and release as 
well as penetrating capability to the cancerous cells, several characterization like DLS, NTA, 
TEM, XRD, FTIR and zeta potential measurement have been performed. 
Drug loading on to the TiO2 nanoparticles was implemented for the drug delivery 
systems. So far, daunorubicin
4
 and doxorubicin
5
 are the two drugs that have been loaded on 
to TiO2 nanoparticles to form the nanocomposites. To the best of my knowledge no 
nanocomposite have been formed with paclitaxel (PCT) and TiO2. PCT is a FDA approved 
anticancer drug that has been used to alleviate breast, ovarian, lung cancer, head and neck 
carcinomas
6
 and also it is stated as the first-line treatment for advanced carcinoma of the 
ovary and non-small cell lung cancer. It is specified for the breast cancer treatment after the 
failure of a combination chemotherapy with doxorubicin or after 6 months of adjuvant 
chemotherapy
7
. Drug efficiency and release kinetics synopsis obtained by HPLC is the most 
significant in the study to claim the pH sensitive PCT-TiO2 nanocomposite as a smart 
nanocarrier. 
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Biological activity of the PCT-TiO2 nanocomposite was corroborated on MCF-7 
breast cancer cell line by performing different biological tests like measuring the uptake rate 
of the cells by flow cytometry, cytotoxicity via MTT assay, and apoptosis analysis was 
conducted by DAPI staining and flow cytometry. 
Chapter 1 throws a detailed knowledge on the nanoparticle properties, significance, 
applications and its role in drug delivery system. Benefits, advantages and disadvantages of 
the anticancer drug is also discussed in this section. Chapter 2 is all about the synthesis and 
characterization of the nanoparticle. The nanocomposite construction and its essential release 
estimation has been highlighted in chapter 3. The final chapter i.e. chapter 4 concludes the 
whole work done by carrying out different experiments to study the biological activity of the 
nanocomposite over MCF-7 breast cancer cell line. 
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CHAPTER 1: Literature Review 
 
1.1 Introduction 
Cancer is the second most leading cause of death worldwide after the cardiovascular 
diseases. Despite all the assistance from the upcoming modern technologies and efforts in 
providing an effective therapy, cancer still remains unconquered because of its unpredictable 
variations inside the body. Cancer can be broadly sorted into three different stages: local, 
regional and distant
8
. The initial stage of malignant cancer where it is confined only to its 
primary organ (origin) is described to be the local stage, which by chemotherapy can be 
curbed and the advancement of cancer towards the surrounding organs can be restricted or 
else it would proceed towards its second stage i.e. the regional stage affecting the nearby 
tissues, organs and the regional lymph nodes. Distant stage is the last stage when many 
lymph nodes from different parts of the body are affected. This type of cancer is recognised 
as metastatic cancer and there is very less chances of survival in this stage.   
Current scenario in India 
After the cervical cancer, breast cancer is a growing problem of concern in India. 
Male breast cancer is rare compared to breast cancer in women. Rajesh Balkrishnan, an 
associate professor at the U-M schools of Pharmacy and Public Health, from his recent 
investigation stated that one in 22 women are likely to suffer from breast cancer
9
. 56% Indian 
patients have large tumours (2-5 cm) in first detection and majority are in grade-III stage, but 
in the west it is caught in the earlier stage
10
. Even the five-year survival rate is 60% in India 
where as it is 79-85% in developed countries. Furthermore, the period of developing breast 
cancer in women in India is a decade earlier to that in western countries. The threat rate is 
higher in metropolitan cities than in rural areas, however, the survival rate in later is very 
low. Breast cancer rate is highly observed in women of higher education and in those 
communities that have adopted westernized lifestyle like Christians, Parsis and women from 
metropolitan cities, it is low in the Muslim community. Experts say by 2015 breast cancer 
cases will double
11
 to surpass the cervical cancer and become the leading cause of death in 
Delhi, Bangalore, Mumbai, Chennai, Bhopal, Ahmedabad and Kolkata with the relative 
proportion ranging from 21.7-28.7%. Number of cases is about 115,000 per year and is 
expected to rise to 250,000 new cases per year by 2015. Few reports even indicate that breast 
cancer has already taken the lead.  
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1.2 Delivery of drugs to tumour sites 
 The main problem in the anticancer drug delivery is that the drugs affect the healthy 
tissues the most rather than the cancer cells, thereby increasing the rate of risk. Delivery of 
drugs should be invoked with selective localization, slow infusions, monitoring of serum drug 
levels, multi-drug regimens and careful timing
12
. Drugs should reach to the target site with 
minimal maiming of the healthy tissues. To accomplish these purposes delivery vehicles for 
drugs come into the limelight. They should be biocompatible, nontoxic, non-immunogenic, 
biodegradable and be able to recognise and avoid the host’s defence mechanism13. Chemical 
conjugation of drugs directly to targeting proteins via the delivery vehicles like liposomes, 
polymeric micelles, synthetic polymers, dendrimers, nanoparticles, artificial DNA 
nanostructures, recombinant antibodies or cell-specific cytokines can cause the steric 
stabilisation, long circulation of particles, controlled release, supplying higher concentration 
of drugs for extended period encouraging long-term drug delivery.  
 Unlike liposomes which express low stability, instantaneous uptake and clearance by 
RES
14
, nanoparticles show the greater advantage of being used as the delivery vehicle due to 
their ability to bypass the clearance by reticuloendothelial system
1
. The high surface energy 
of nanoparticles permits them to accommodate numerous drug molecules and their small size 
is advantageous for attaching to multivalent targeting ligands. Once the nanoparticles are 
attached to the cell it is prelude to uptake because of their relative lack of shear stress. Their 
0 10 20 30 40
Hyderabad
Kolkata
Bangalore
Chennai
Bhopal
Mumbai
Delhi
Chandigarh
12.7 
14.3 
22.8 
23.5 
23.7 
26.7 
28.9 
39.5 
Rate per 100,000 
Figure 1: District-wise comparisons of age-adjusted breast cancer incidence rates (per 
100,000) under the National Cancer Registry Programme, ICMR, supported by WHO. 
Source: NCRP, Bangalore. 
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ability to bypass the drug resistance mechanism makes it a valuable aid in drug delivery 
system in an effort to increase the bioavailability of drugs at the intended site of action
12
. 
 
1.3 Delivery of nanoparticles to tumour sites  
Targeting of nanoparticles to the site of tumour can be described by two types of 
mechanisms
15
, active targeting and passive targeting. Active targeting is an energy dependent 
mechanism that involves the conjugation of a tumour specific ligand to the nanoparticle for 
targeted delivery of drugs. Tumour antigens, tumour vasculature and cell surface receptors 
act as the target site of tumours, bind with the targeting moieties like antibodies, peptides, cell 
surface ligands, and aptamers. In preclinical models, targeting has variably led to increased 
accumulation in tumours. In many instances, cancer cell uptake has been increased with 
targeting without increase in overall tumour accumulation of nanoparticles. 
Passive targeting involves the accumulation of nanoparticles in the endothelium of the 
tumour blood vessels via their abnormal gap junctions which ranges from 100-600 nm in 
size, thus making this mechanism an energy independent one
.
 Altered lymph drainage is a 
characteristic of tumours which favours retention of nanoparticles inside tumours. In general, 
small particle size is thought to favour intratumoural extravasation. Even though the active 
targeting mechanism is a much preferred one, the novel approach of delivery of nanoparticle 
to the site of tumour is still under probation.   
 
1.4 Titania nanoparticles as drug delivery system 
Metallic nanoparticles like Fe2O3, Ag, ZnO and Au are also used for different 
therapeutics, diagnosis and treatment of cancer cells, but they come with certain drawbacks 
like during the production of Fe2O3 nanoparticles, FeO nanoparticles are also formed as one is 
the by-product of the other and it is very difficult to completely isolate the two different 
nanoparticles and thus their mechanism of action for drug loading and therapeutic activities 
cannot be assured
16
. Silver nanoparticles on account of their antimicrobial properties have 
gained much popularity and are extensively used in detergents and wound dressings that end 
up in the environment in form up waste disposals. It has been reported that at the same 
concentration ultrafine particles can cause more damage than larger particles
17
. The toxicity 
of ZnO nanoparticles to T cells fall above 5 mM and the tolerance level to neuroblastoma 
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cells is above 1.2 mM
18
 where as for TiO2 nanoparticles the tolerance level is above 10 mM
19 
and moreover TiO2 nanoparticles are pH sensitive unlike gold nanoparticles
20
. 
TiO2 nanoparticles also have semiconductor properties i.e. when they are excited by 
UV or near-UV radiation they generate free electrons and free holes with consequent 
production of reactive oxygen species which are very powerful oxidants and can damage the 
cell membrane leading to the inactivation of the cell. Thus TiO2 nanoparticles produce an 
antimicrobial effect, killing microorganisms or reducing their growth
21
.  
TiO2 nanoparticles can also cause inflammation, pulmonary damage, DNA damage 
and fibriosis
22
. Nanoparticles interact with the immune system by entering into the human 
stratum corneum. There might also cause an increase in the level of cellular nitric oxide in 
human bronchial epithelial cells, in addition to the oxidative DNA damage. However, it is 
reported that titania has a low toxicity
23
 and no conclusion of carcinogenicity in humans
24
. 
Moreover, they remain intact in inter and intracellular areas of the cell for clear detection 
instead of getting digested by the cell
25
. This makes them an ideal material for safe cancer 
treatments in humans. Surface defects present in TiO2 nanoparticles smaller than 20 nm 
makes them reactive that results in binding with a variety of ligands on the surface. These 
properties are extremely useful for attaching drugs for an improved drug delivery system, 
from using TiO2 as a drug encapsulating agent to using it as a drug surface carrier
4
.  
 
1.5 Properties and applications of TiO2 nanoparticles 
Titanium is the ninth most abundant element on earth and titania is a naturally 
occurring mineral. TiO2 has been proven to be the most suitable for widespread 
environmental applications due to its many merits such as TiO2 possesses good optical and 
electronic properties, the catalyst is stable, non-toxic, cheap, biologically and chemically inert 
and insoluble under most conditions, non-radioactive and reusable. It is commercially readily 
available and cost-effective. In addition to the high surface area nanoparticles and excellent 
biocompatibility TiO2 has another unique property of having a high affinity toward phosphate 
moieties. Also TiO2 photocatalyst shows a higher photocatalytic activity in comparison with 
the other photocatalysts.  
 
TiO2 nanoparticles in aqueous solution form surface hydroxyl groups due to 
dissociative chemisorption of H2O molecules on the oxide layer. Depending upon the pH & 
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ionic environment of the suspension medium the surface groups acquire or release protons; 
adding to their acid-base properties of the oxide and providing a charge on the surface. This 
strong redox ability of the TiO2 nanoparticles makes them useful for photochemical cells, in 
water or air purification, in degrading the organic pollutants and killing bacteria
26
.  
 
They absorb UV light and are used in sunscreen lotions and other cosmetics. They are 
found as a pigment in powder form and are added to products such as paints, toothpastes, 
papers, coating plastics, to give them a white colour that lasts years. 
 
Out of the three phases of TiO2 anatase has higher electron mobility, lower fixed 
dielectric properties and lower density
27
 useful in photocatalytic applications. Other 
applications in various fields include self-cleaning, gas sensing and sensor devices, dye-
sensitised solar cells, electroluminescent hybrid devices, energy-storage technologies, 
electrodes in lithium batteries and water-splitting catalysts for generating hydrogen.  
Types of drugs used for nanocomposite formation with TiO2 
 So far to the best of my knowledge, daunorubicin and doxorubicin are the two drugs 
that have been loaded on to the TiO2 nanoparticles to form the nanocomposites for the drug 
delivery systems. The cytotoxic effects, anticancer efficacy enhancement, side effect 
attenuation of doxorubicin-TiO2 nanocomposites in human SMMC-7721 hepatocarcinoma 
cells were investigated by Chen et al and the drug release behavior with respect to different 
pH values, the tumour cellular uptake along with the cytotoxicity of daunorubicin-TiO2 
nanocomposites in K562 leukemia cells were evaluated by Zhang et al. Both concluded that 
these two drugs conjugated with TiO2 nanoparticles hold promising approach as a drug 
delivery system for clinical practices.  
 
1.6 Paclitaxel 
 Paclitaxel (PCT) is a highly potent anticancer agent that is obtained by isolating from 
the bark of the Pacific Yew tree Taxus brevifolia. Also known as Taxol, at extremely low 
concentrations this chemotherapy drug efficiently inhibits cell growth attracting much 
attention. As reported by Jordan, Toso et al. during the G2-M phase of the cell cycle PCT 
binds to a region of β-tubulin monomers that hyperstabilizes the microtubules by preventing 
depolymerization. Dynamic instability creates successful division of chromosomes and 
cessation of cell division as the metaphase spindle configuration is not achieved. The 
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prolonged spindle assembly checkpoint causes cell death
20.
 Owing to this extraordinary 
characteristic of the drug, they are treated to kill cancer cells. So far it has been used to 
alleviate breast, ovarian, lung cancer, head and neck carcinomas
6
, but its usage is not limited. 
For the treatment of advanced carcinoma of the ovary and non-small cell lung cancer, PCT is 
specified as the first-line treatment. It is specified for the breast cancer treatment after the 
failure of a combination chemotherapy of PCT and doxorubicin or after 6 months of adjuvant 
chemotherapy
7
. 
 Even when PCT is a novel antimicrotubule agent, it still comes with certain and major 
drawbacks like the lack of ability to distinguish between a cancer cell and a normal cell. It 
destroys the immune system along with causing serious problems in the digestive tract
20
. This 
is why it should be associated with a carrier vehicle like nanoparticles that would target only 
the cancer cells and not the healthy tissues. Furthermore, there is no such authenticated 
clinical marker available that would help predict the sensitivity of the drug
28
. It is insoluble in 
water due to its hydrophobicity and before administration it must be dissolved in a mixture of 
cremophor EL and ethanol and unfortunately premedication of steroids and antihistamines 
are required before PCT administration due to hypersensitivity caused by cremophor EL
29
. 
 Abraxane, the albumin-bound PCT is the available formulation in the market 
approved by the U.S. Food and Drug Administration for treating breast cancer, ovarian 
cancer, non-small cell lung cancer and AIDS related Kaposi sarcoma.  
Work done with PCT so far 
 A comparative study of PCT with doxorubicin showed its inferiority; however, it is 
equivalent to CMFP chemotherapy as front line treatment for patients with metastatic breast 
cancer
30
. Taxane based neoadjuvant and adjuvant therapy study, prediction of PCT sensitivity 
by CDK1 and CDK2 activity and correlation of PCT with autophagy in human breast cancer 
cells, in vivo and in vitro evaluation on the delivery of PCT in improving local therapy for 
lung and breast cancer by loading the drug onto a polymeric nanoparticle, together with an 
efficacy comparison with the drug alone, developing peptide-conjugated biodegradable 
nanoparticles as a carrier to tumour neovasculature and a gold nanoparticle based drug 
delivery system, conjugating PCT to iron oxide nanoparticles for tumour imaging and 
therapy, creating formulations of PCT-lipid nanoparticles conjugates and polymeric micelles-
PCT conjugates for improved therapeutic and treatment of metastatic breast cancer, 
incorporation of the drug into EGF-conjugated nanoparticles and even producing a PCT-
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conjugated AAV nanoparticles for targeted delivery to breast cells and limiting the exposure 
of drugs to normal non-breast tissues have already been reported. 
 
1.7 Hypothesis 
Drug entrapment can be possible through complexation with transition metal ions. 
Since transition metals show variable valence with respect to pH of its surrounding 
environment, it is possible that the drug release can be regulated to site specificity through 
adjustment of pH in case of the transition metal encapsulating the drug. Therefore, we are in 
the opinion that TiO2 nanoparticles loaded with PCT would be able to be directed for 
cancerous cells as its pH is acidic in nature. Moreover, the release will be further enhanced 
near lysosomes and vesicles so that the effective toxicity will be enhanced.  
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CHAPTER 2: Synthesis and Characterization of Titania Nanoparticles 
 
2.1 Introduction 
 Titania nanoparticles synthesis can be done by various techniques. Industrial 
preparation contains impurities and degrades the quality of the product (Zhanga T., 2006). 
Chemical precipitation may give highly pure sol-gel products but it is difficult to control the 
crystal size distribution
31
. Another procedure is hydrothermal method that includes aqueous 
or non-aqueous solutions as the starting material and involves the application of elevated 
temperature and pressure to the solution. TiO2 nanoparticles obtained from sol-gel route are 
highly crystalline clear spherical non-homogeneous structures with a diameter of  9 nm, while 
those obtained via hydrothermal methods are not clear spherical structures, they adhered to 
one another and agglomeration is more with average particle size is ~19 nm
32
. In this report, 
the high temperature hydrolysis of TiOSO4 aqueous solutions is adopted to synthesise 
nanocrystalline anatase TiO2 powders described below. 
 
2.2 Preparation of TiO2 nanoparticles 
 200 mL H2SO4 was taken in a beaker and heated inside the fume hood chamber. 80 
gm (NH4)2SO4 was added periodically to it with continuous stirring. Fumes were produced as 
the reaction was exothermic. After the complete addition of (NH4)2SO4 to the H2SO4 it was 
left for 5-10 minutes and then 10 gm TiO2 powder was added to the solution in intervals of 10 
minutes. After all the TiO2 powders were added the solution it was left to cool at room 
temperature for 24 hours. Now the cooled solution was added to 600 mL of distilled water 
with continuous stirring. After the dilution process was completed the solution was again left 
to cool at room temperature for 2 hours. 
 The solution was kept inside the ice bath and 600 mL NH4OH was added till the 
formation of a white precipitate takes place. Millipore water was poured for washing and the 
precipitate was left to settle down. The supernatant was discarded and again the precipitate 
was washed. This repeated cycle of washing and discarding the supernatant was carried out 
till the solution’s pH reaches 7. Filtration was done and the filtered residues were dried. Later 
they were transferred to a beaker, sealed and put inside the freezer at -20
0
C for 2 hours and 
then left overnight at -80
0
C. After 24 hours of freeze drying, the residues were fired at 700
0
C. 
Dry powders of TiO2 nanoparticles were obtained and stored at 4
0
C. 
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2.3 Characterization 
In order to meet the specific criteria for penetration of nanoparticles and also to be a 
potential material for drug loading into the cancerous cells, it is required to understand certain 
physicochemical properties of the nanoparticles that is achieved by the following 
characterisations: 
2.3.1 Dynamic light scattering (DLS) 
DLS is a useful tool to determine the agglomeration state of nanoparticles as a 
function of time or suspending solution. It characterizes the size of a colloidal particle in a 
solution and measures the hydrodynamic size of a particle. DLS ZS-90 (Malvern, UK) was 
used here to measure the particle size. 
2.3.2 Nanoparticle tracking analysis (NTA) 
NTA tracks the Brownian motion, counts and discriminates every particle in the 
liquid suspension whose speed of motion helps in determining a thorough size distribution 
analysis. Measurements were performed at room temperature with a NanoSight LM20, 
equipped with a sample chamber with a 640 nm laser and a Viton fluoroelastomer O-ring. 
NTA 2.0 Build 127 software was used for capturing and analyzing the data.  
2.3.3 Transmission electron microscopy (TEM) 
TEM is the most powerful microscope with a significantly higher resolution (by a 
factor of about 1000) than light-based imaging techniques, providing the quantitative 
measurement of the particle size, size distribution, and morphological, topographical, 
compositional and crystalline information. 200 kV TEM JEOL 2000FX was used for the 
observation of the dried TiO2 nanoparticles supernatant solution.  
2.3.4 X-ray diffraction (XRD) 
The phase analysis of the nanoparticles was carried out by XRD. The dried TiO2 
nanoparticle powders were put on the sample holder and characterized by using a Shimadzu, 
XRD-6000 with Cu Kα radiation (1.5418 Å). Scanning range was set from 20-80
0
C with scan 
speed of 2
0
C/minute.  
 
Titania Nanoparticles for the Intracellular Delivery of Paclitaxel in Breast Cancers 
 
 
12 
2.3.5 Zeta potential analyser 
Zeta potential determines the interparticle forces in dispersion stability. ZetaSizer 
Nano ZS (Malvern Instruments) is used to measure the zeta potential of the nanoparticles. In 
the DTS software the required parameters were entered, temperature set at 25
0
C and the data 
was analysed.  
2.3.6 Fourier transform infrared spectroscopy (FTIR) 
The chemical composition of any sample can be easily determined by FTIR. Here, 
FTIR spectrophotometer (Shimadzu) interfaced with IR microscope was operated in 
reflectance mode. The spectra were acquired in the 4000-400 cm
-1
 region with 8 cm
-1
 
resolution, 60 scans and beam spot size of 20-100 μm. 
 
2.4 Results and Discussions 
2.4.1 Particle size 
Size and shape are the key features that govern the physical stability of TiO2 
nanoparticles, both in vitro and in vivo
33
. The size strongly influences the flow of the 
particles and their subsequent response to the cancerous tissues. The decrease in particle size 
results in an increase of the surface area, which may have important implications on the 
noncrystalline character of the particles and consequently on their flow behaviour. The 
techniques that are generally employed for the determination of mean particle size and size 
distributions include DLS, NTA and TEM.  
TABLE 2.1: The size distribution measurement of the nanoparticles by DLS 
 Size (r.nm) % Intensity Width (r.nm) 
Z-Average (r.nm): 297.2 Peak 1: 33.14 100.0 2.060 
Pdl: 1.000 Peak 2: 0.000 0.0 0.000 
Intercept: 1.27 Peak 3: 0.000 0.0 0.000 
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Figure 2.1: Size distribution by intensity obtained from DLS 
TiO2 nanoparticles average size from DLS, was found to be 33.14 nm. 
     
Figure 2.2 TEM images of TiO2 nanoparticles at scale bar (a) 1µm and (b) 100 nm 
TEM images of a small portion of area containing very low particle density showed 
that the particle size was within 30-40 nm. They are spherical in shape and individual 
particles do not aggregate among themselves.  
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NTA results determined more than 50% of particles aggregate in <100 nm dimension. 
A concrete understanding of the particle size and concentration dependent dimension is able 
to predict drug loading and encapsulation efficiency and hence helpful in determining the 
effectiveness of drug-carrier conjugate in site dependent action. Therefore, simultaneous 
characterization through TEM and NTA is significantly valuable in drug delivery 
application. Simultaneous measurement of DLS and NTA show that the sample is 
monodisperse in nature.  
Even though DLS and NTA allow the analysis of particle size in a liquid suspension 
through Stokes-Einstein equation, NTA analyses the suspension on a particle by particle 
basis
34
. By NTA not only the particle diffusion but also its hydrodynamic diameter can be 
determined. Whereas, it is not by particle basis in DLS but through a digital correlation time 
dependent scattering intensity fluctuation. DLS measures the relative Brownian movement of 
particles through assemblage of large number of particles within a sample. It provides a 
volume distribution of particle size in contrast to number frequency distribution and relative 
particle concentration in NTA. NTA is insensitive to contaminants and concentration required 
is also less than that of DLS.  
2.4.2 Particle structure 
The structures of composite particles made of TiO2 and organic molecules such as 
ligands/drug as well as the nature of the interactions between the TiO2 core and the associated 
molecular structures within the composite (e.g., chemical association and/or physical 
adsorption) have been investigated through FTIR. In this context, the electrophoretic mobility 
determinations are useful in evaluating the effect of the coatings on the zeta potential (ζ). 
The FTIR study provides with the functional groups present in the TiO2 nanoparticles. 
1633 cm
-1 
shows the bending vibration of O-H, 1350–1400 cm-1 ranges the CO2 absorption, 
the broad band below 900 cm
-1 
is the characteristics of TiO2 and around 3400 cm
-1 
the 
stretching vibration of O-H of absorbed water molecule is detected. 
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Figure 2.4 FTIR spectra of TiO2 nanoparticles 
The adsorption mechanism of organic additive particles involves mononuclear or 
binuclear chelation. These bindings are suggested to be occurring via salicylate or catecholate 
or carbamide type of binding which involves two adjacent OH groups or adjacent COOH and 
OH or COOH and NH2 or OH and NH2 groups providing strong adsorption to form 
negatively charged particles
35
. Therefore the above study suggests that there will be a high 
rate of adsorption of PCT over TiO2 nanoparticles. 
2.4.3 Phase analysis 
The appropriate mineralogical purity and the degree of crystallinity of TiO2 define 
their physiochemical and biological properties. X-ray diffraction can be considered as the 
most important technique to elucidate the phase of the nanoparticle
33
.  
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Figure 2.5: XRD profile of TiO2 nanoparticles 
XRD results indicates nearly complete crystallization of TiO2 nanoparticles. However, 
retention of some unsharp spots and peaks with surrounding scattered sample indicated slight 
disorderness of sample. All the identified peaks are proof to be the anatase phase of the TiO2 
and the corresponding diffraction plane are marked in the figure 2.5. The anatase phase of 
titanium nanoparticle has long been known for its application in implant. It is corrosion 
resistant that ensures minimum inflammation inside the body. TiO2 nanoparticles in their 
anatase phase are important because the protein molecules that bind with the nanoparticles 
fold themselves inside the body in a way favourable enough to easily escape the clearance by 
reticuloendothelial system
1
 and thus they reside for an extended period inside the body. 
2.4.4 Surface charge and stability 
The surface properties of nanoparticles are significant in determining the drug carrier 
potential since they control the interaction with plasma proteins. Zeta potential measurement 
informs about the overall surface charge of the particles and how it is affected by the 
environment
33
 (e.g. pH, presence of counter ions, adsorption of proteins and its duration of 
passage with blood flow). The charge shielding by several groups (natural or artificial) may 
be used for predicting the effectiveness of the barrier function against opsonisation in vivo. 
Zeta potential can be used to determine the type of interaction between the drug and the 
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carrier i.e. whether the drug is encapsulated within the body of the particle or simply 
adsorbed on the surface. This is important because adsorbed drug may not be protected from 
enzymatic degradation or may be released very rapidly after administration. Its contribution 
to characterize drug carrier system can be analysed by observing the drug loading and drug 
release profile. When the zeta potential is greater than +25 mV and lesser than -25 mV the 
particles have high degrees of stability.  
TABLE 2.2: Zeta potential distribution 
 Size (r.nm) % Intensity Width (r.nm) 
Zeta Potential (mV): -28.2 Peak 1: -28.2 100.0 3.70 
Zeta Deviation (mV): 3.70 Peak 2: 0.000 0.0 0.000 
Conductivity (mS/cm): 0.00699 Peak 3: 0.000 0.0 0.000 
 
 
Figure 2.6: Zeta potential distribution 
From the Table 2.2 and Fig. 2.6, it was observed that the zeta potential for the 
nanoparticle was -28.2 mV which indicated greater stability. The influence of pH on the zeta 
potential is completely different. Polymeric nanoparticles prepared without surfactants have 
the value close to zero for all but a narrow window around neutrality, indicating their 
aggregation in acidic or basic medium. On the other hand particles prepared with surfactants 
had a constant zeta potential irrespective of pH as the surfactant prevented the binding of 
counter ions within its cavity, so stability can be expected
36
. 
Salt concentration also affects zeta potential. It also varies from type and molecular 
weight of the salt and concentration of CaCl2 cause the zeta potential to rise to a plateau at 
zero which is accompanied by aggregation of nanoparticles. The divalent Ca
2+ 
thus acts as a 
bridging ion but Na
+
 acts as uniquely adsorbed ion which not only screens the zeta potential 
but reverses it as the concentration of salt increases. So surfactants have little role in this 
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respect. Hence, the particles are expected to have a positive charge in physiological salt 
condition and be sensitive to aggregation by divalent cations like Ca
2+
. 
Long circulating nanoparticles are expected to inhibit compliment activation
36
. This 
zeta potential measurement helps to identify the presence of protein over the nanoparticle and 
the type of folding that is induced. Drug loading and surfactants can shield the zeta potential 
of the nanoparticles. Sometimes it may also happen that the negative charge can be shielded 
to positive that would determine the heavy loading not only by drugs but by other molecules. 
Thus the behaviour of surface adsorbed drugs can be studied by zeta potential measurement. 
This zeta potential serve as an important tool for characterizing controlled drug delivery 
system, providing information regarding the surface properties of nanoparticles and therefore 
determine the organization of the constituent molecules. Incorporation of drug molecules 
changes the zeta potential indicating the mode of association and its release in different 
media. It can also be used to follow the adsorption of plasma protein and other molecules 
onto surface.  
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CHAPTER 3: Drug Loading, Drug Encapsulation and Drug Release 
 
3.1 Introduction 
 Drug loading and encapsulation varies with the different drug delivery vehicles like 
nanocarriers, liposomes, micelles etc. and also with different kinds of drugs. However, the 
site specificity depends mainly on the type of nanocarrier used. The rate and duration of 
dissolution of drug depends on the nature of nanocarrier as well as the type of salt crystal and 
co-crystals used. Use of nanocrystals in conjugation with nanocarriers may enhance the drug 
dissolution for sparingly soluble and also hydrophobic drugs. This will lead to a reduction in 
the dosing frequency with improved therapeutic competence since it leads to controlled and 
sustained release of the drug. An effective and supportive surface functionalization strategy 
prolongs the therapeutic half-life time in vivo acknowledging circumvention of the immune 
system and targeted delivery
37
. These advantages indicate use of lower amount of drug, 
reducing cost and relatively intricate preparation procedure
38
. Nevertheless the greatest 
advantage of the nanocarrier drug delivery system is decreased patient complicacy due to 
reduction in dosing frequency with increased tolerability to drugs.  
Improvement in analytical system is done to accurately analyse the plasma 
concentration of blood and correlate these data with the in vitro measurements performed in 
association with this. In this context, the current study throws light on the construction of the 
PCT-TiO2 nanocomposite, drug release mechanisms, drug loading, drug encapsulation and its 
efficiency measurement by HPLC. 
 
3.2 Drug release by HPLC 
Drug release rate at direct real time measurements are extremely essential in 
understanding and unswerving assessment of its kinetics. This measurement can be done by 
various techniques out of which high performance liquid chromatography (HPLC) is the most 
preferable. 
It is the most important analytical technique carried out during the drug 
manufacturing procedures because to ensure a drug’s safety and quality intensive and high 
level of investigation of chemical support at all stages is thoroughly required. In this HPLC 
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system, the chromatographic dilution of a sample under isocratic elution condition is 
expressed by the following equation
39
: 
  
  
    
 
    (   )√    
    
 
Where C0 is the initial compound concentration in a sample before injection into the HPLC. 
Cmax is the final compound concentration at the peak maximum. 
r is the column radius  
k is the retention factor 
L is the length of the column 
H is the column plate height 
ε is the column porosity  
Vinj is the volume of sample injected 
 
3.3 Materials and Methods 
3.3.1 Construction of PCT-TiO2 nanocomposites 
 2 mL aqueous solution of PCT (0.5 mg/mL) was poured in 1 mL aqueous solution of 
TiO2 nanoparticles and three such samples were prepared. The mixture was continuously 
agitated using a stirrer at 50 g and left overnight in dark to allow the construction of 
nanocomposites. All the three samples were observed after 12 hours, 24 hours and 48 hours 
respectively. The nanocomposites formed were separated from the free standing molecules by 
centrifuging at 5000 g for 30 minutes. The supernatant was determined by high performance 
liquid chromatography and its loading and encapsulation efficiencies were estimated. 
3.3.2 Loading efficiency of drug 
 Five identical formulations were prepared to find out the loading efficiency of the 
PCT-TiO2 nanocomposite. The loading efficiency of a drug is defined as the percentage of 
ratio of the amount of drug in the nanocomposite formed to the amount of PCT-TiO2 
nanocomposites. 
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3.3.3 Encapsulation efficiency of drug 
 Here also five identical formulations were prepared and the encapsulation efficiency 
was calculated by the percentage of ratio of the amount of drug in PCT-TiO2 nanocomposites 
formed to the initial amount of drug used. 
 
3.3.4 Drug release study 
 The release behaviour of PCT from PCT-TiO2 nanocomposites was investigated at pH 
5.2, 6.0 and 7.4 which are the pHs of endosomes or lysosomes, tumour cells and 
physiological blood respectively. PCT loaded TiO2 nanoparticles (20 mg) were dispersed in 
PBS (pH 7.4, 5 mL) and transferred into a dialysis bag (Pierce, Biotech, thermo Scientific). 
The dialysis bag was then immersed in 95 mL PBS at pH 5.2, 6.0 and 7.4. The release 
medium was continuously agitated with a stirrer at 50 g and 37°C. After desired time 
intervals of 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 36 and 48 hours, 2 mL of the medium was 
collected and replaced with the same fresh PBS. The amount of released PCT in the medium 
was then determined by HPLC. 
3.3.5 HPLC  
Standard drug PCT was purchased from Sigma aldrich. HPLC grade acetonitrile, 
glacial acetic acid, trifluroacetic acid and hydrochloric acid were procured from Merck Ltd., 
India. Analytical grade NaOH, hydrogen peroxide and other chemicals used in the study were 
procured from CDH chemicals Ltd, Mumbai, India. The HPLC system (Shimadzu, Japan) 
consists of a LC-10AT pump, a SPD-10AVP, PDA detector, Phenomenex C18 (250 mm X 
4.6 mm, 5 μm) column, a Phenomenex, HPLC grade cartridge system and a class Nuchrom 
software. pH of the mobile phase was checked on microprocessor based water proof pH tester 
(pH tester 20, Eutech instruments, Oakton, USA). The overall illumination at the point of 
sample placement was tested using a calibrated lux meter (Lutron). Stability study was 
performed in a hot air oven (oven universal with Thermotech thermostat TIC-4000N, S.M. 
Industries, New Delhi, India). The mobile phase found to be most suitable for analysis was 
acetonitrile:phosphate buffer pH 7.4 in the ratio of 60:40. Flow rate employed for analysis 
was 1.0 mL/min and the concentrations were detected at 226 nm. The concentration of 
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released sample after predetermined time intervals are quantitatively estimated through 
HPLC analysis with reference to standard estimation.  
 
 
3.4 Results and Discussions 
3.4.1 Efficiency 
TABLE 3.1: Loading and encapsulation efficiency of drug 
Formulations Loading Efficiency (%) Encapsulation Efficiency (%) 
F1 17.34 ± 3.534 62.67 ± 0.884 
F2 21.56 ± 5.476 65.12 ± 2.280 
F3 18.08 ± 1.299 59.34 ± 18.233 
F4  18.94 ± 0.078 67.48 ± 14.977 
F5 20.18 ± 0.922 63.45 ± 0.026 
Average 19.22 63.61 
 
The efficiency of nanoparticles can be obtained by measuring the loading efficiency 
of PCT. Study revealed that the average loading efficiency of PCT was 19.22 ± 1.22%. 
However encapsulation efficiency that determine the affinity of the nanocomposite towards a 
biological system showed substantially higher efficiency of PCT over TiO2 nanoparticles i.e. 
63.61%. As per the selective diffusion theory, when surface moisture is within 7-23%, the 
surface of particle acts as a semipermeable membrane and so reduces the diffusion of drugs 
to the core. This encapsulation efficiency in case of drugs in solution is dependent on 
concentration, molecular weight and polarity. However, in case of TiO2 nanoparticles, this is 
dependent on surface area of the nanoparticles. 
3.4.2 Drug release study 
The efficiency of drug release can be obtained through release of drug into the outer 
in vitro medium. The reduction in rate of drug release decreases the diffusivity of a high 
molecular weight drug like PCT. Study does not explicitly claim a relationship of drug 
release with respect to the nanocomposite but, however it provides a gross overview 
regarding the amount of drug released into the cancerous cells. 
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TABLE 3.2: HPLC drug release study of PCT into SBF at different pHs  
 
The drug release into the medium estimated through HPLC was plotted in a graph to 
find the kinetics of release of drug.  
 
Figure 3.1: Time vs cumulative release of drug at pH 5.2, 6.0 and 7.4 
The preparative HPLC is a standard method to determine the amount of drug loading 
and drug release. The selection of mobile phase should not oxidise/degrade the drug to many 
other compounds which may interfere in analysis. The compound where degradation kinetics 
 
Time (hours) 
Cumulative release (µg) 
pH 7.4  pH 6.0 pH 5.2 
2  06.511±0.667 19.201±1.661 35.091±1.865 
4 10.134±0.912 32.312±1.378 52.824±1.765 
6 12.392 ±0.887 41.513±1.993 67.367±2.145 
8 14.456±1.239 51.632±2.011 73.452±2.008 
10 15.125±1.116 58.159±1.066 76.339±1.854 
12 16.306±1.457 60.732±0.966 80.156±1.764 
16 17.407±0.995 63.269±0.858 83.336±1.349 
20 18.892±1.095 65.335±0.546 84.542±0.987 
24 19.134±1.342 65.850±1.662 85.192±0.764 
28 19.238±1.056 68.133±0.568 85.344±0.682 
36 19.230±0.867 69.254±0.874 86.104±0.943 
48 20.341±1.667 70.023±0.483 87.197±1.765 
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is very fast, methanol can be replaced for acetonitrile. However, in this case a small peak 
appeared in the chromatogram after 22 minutes which may correspond to either impurity or a 
degraded product. Since a large time interval is observed, this peak may correspond to 
impurities. There may be so many other degraded products formed during the retention time 
of drug in mobile phase which cannot be detected through the PDA detector. A versatile 
detector like ELSD can be used for this case but due to lack of facility this turned out to be 
the limitation in this study. The detection of degraded products holds significant importance 
due to the fact that early knowledge of the same can be helpful in evaluating stability of the 
drug and toxicity to patient. 
The quantitative analysis of PCT released into the SBF after dialysis through slide-A-
lyzer cassette has been analyzed through HPLC. All the 4 steps like sample preparation, assay 
calibration, sample analysis and data management has been performed sequentially to achieve 
maximum accuracy with desired precision. The pure PCT (100 ng) has been used as internal 
standard. The standard curve has been plotted ranging from 1-100 μg and in case of higher 
concentration, serial dilution technique has been applied to bring the concentration to the 
desired limit. Every care has been undertaken to minimize the error. The first peak arises 
after 8 minutes and the AUC (area under the curve) is calculated for a predetermined amount 
of sample and normalized for all other types of testing sample. The table 3.2 and figure 3.1 
represent detailed description of quantitative release of PCT to the in vitro medium. 
Study proved the pH specific release of PCT to simulated body fluid at different pH 
similar to extra cellular fluid. In the case of cumulative release the point of inflexion (mild) 
occurs after 12-16 hours. After that nearly a stationary phase is maintained up to 48 hours. 
The difference in drug release rate i.e. normal body pH to cancerous site is nearly 4 times. 
This indicates the specificity of PCT release effectively near the cancer site. It indicates 
nearly complete release of within 12 to 16 hours of injection. However the study requires to 
be verified in the context of in vivo medium in order to find its suitability in presence of 
various body protein. 
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Figure 3.2: Dot plot of HPLC showing PCT release into SBF 
 
Figure 3.3: Machine generated data of HPLC 
Mechanism Of Differential Release: 
Titanium is a transition metal with +2 and +4 valencies. The hydrated TiO2 surface is 
amphoteric in nature and results in pH-dependent equilibrium between protonated and 
deprotonated hydrous surface species. TiO2 nanoparticles obtained from hydrolytic synthesis, 
if treated with NaOH or NH3 in water, it will reverse its charge and there will be a certain 
degree of aggregation. The ionization state of the TiO2 surface at different pH is as follows: 
At pH < 6.7:                                  
                          
     
At pH > 6.7:                                 
                              (Reaction – 2) 
(Reaction – 1) 
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Below pH 6.7 the TiO2 nanoparticles remain positively charged. This protonation of 
drug occurring at low pH releases chemisorbed drug molecules into the medium
40
. Since the 
nanoparticle is positively charged the electrostatic interaction of PCT and TiO2 nanoparticles 
is blocked facilitating drug release. TiOH
+ 
creates random hole in the membrane and hence 
simultaneous entry of drug and nanoparticle into the cell occurs. 
PCT-TiO2 nanocomposite remains in the blood for a prolonged time period and 
greatly reduces the side effect to normal tissue. After the creation of hole, the entry of TiO2 
loaded with PCT occurs due to large size of holes. The larger the value of pKa the smaller is 
the extent of dissociation at any given pH. 
PCT-TiO2 complexation is favourable and stable at pH > 6.7. Thus the release of drug 
near normal cells is not possible. Negatively charged TiO2 acts as a Ca
2+
 scavenger
40,41
 along 
with drug and lipid forming a very stable complex preventing the attachment of TiO2 into 
lipid membrane. This complex formation has pKa value 0-0.58 at pH < 6.7 and 1.858 at pH > 
6.7.  
 
Figure 3.4: In the presence of TiO2 nanoparticles, Ca
2+
 accumulate at the lipid-TiO2 
interface, leading to the removal of Ca
2+
 ions, as well as whole membrane patches, from the 
substrate (Zhao et al. 2012). 
At the cellular level, CaPO4 is present at the lipid surface. When the TiO2 
nanoparticles reaches the cell surface the Ca
2+ 
interacts with the TiO2 i.e. Ca
2+
 accumulates at 
the lipid-TiO2 interface and destabilizes the CaPO4 interaction disturbing the fluid mosaic 
model. This disturbance reduces the membrane potential and pores are created on the 
substrate as a whole membrane patch is removed along with the Ca
2+
. Ion exchange takes 
place through these pores in order to reach equilibrium and the nanoparticles get released into 
the cells. Due to the steric hindrance
41
 of the CaPO4-TiO2 complex, the drugs don’t get 
released into the normal cells but this doesn’t stop the nanoparticle carrying the drug from 
penetrating into the cancerous cell.  
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Then again, there is also the possibility of physical damage to cell membranes by 
TiO2 nanoparticles, as the creation of the pores facilitates the entry of TiO2 into the cell. The 
photocatalytic properties of nano-TiO2 under UV irradiation causes photo-oxidative stress 
that induces the decrease of skin cell stiffness, causes DNA damage, lipid peroxidation and 
protein damage
42
, which if effectively countered by cellular antioxidant defences can prevent 
cell death. While beneficial for numerous reasons, the design and use of TiO2 nanoparticles 
for various applications necessitates a cautious and skilful approach.  
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CHAPTER 4: Biological activity of PCT-TiO2 nanocomposite over MCF-7 
Breast Cancer Cell Line 
 
4.1 Drug effects on cells 
One of the major problems that restricts the efficacy of chemotherapeutic agents used 
for cancer treatment is the drug resistance capacity of the tumour cells. Even prior to the 
chemotherapy treatments, tumours may be inherently resistant to the drugs used. It can also 
happen that initially the tumour cells are sensitive to the drugs and the resistance capacity is 
acquired during the treatment
43
. This type of resistance is known as acquired resistance. 
However, such acquired resistance gets exasperating when the tumours also become defiance 
to other drugs and with different action mechanisms. Over 90% of cases with metastatic 
cancer is deemed to cause treatment failure because of this innate or acquired resistance 
faculty of the tumours. If this major problem can be gradually overcome then there would be 
a significant rise in success rate for the cure of cancer patients.  
Mechanisms that influence the tumour environment and regulate drug uptake of 
tumour cells determine the sensitivity of a drug. The resistivity to chemotherapy can develop 
at any stage that comprises of various amendments in drug processing like increasing the 
drug efflux, shifting the target, lowering drug influx, inactivating the drug, administering the 
damage caused by the drugs and dodging of apoptosis. In this chapter different tests are 
carried out on the MCF-7 breast cancer cells to have a proper understanding of the tumours’ 
response to the drug and the outcome of these responses. 
 
4.2 Materials and Methods 
4.2.1 Cell culture 
Maintained MCF-7 breast cancer cell lines were cultured in the cancer culture 
laboratory with proper safety measures at IICB, Kolkata. In brief, first inside the tissue 
culture hood, the culture media was prepared that consists of DMEM, 10% FBS, 0.1 mM 
MEM Non-Essential Amino Acids, 2 mM L-glutamine and 1% Pen-Strep. The freezing 
medium is composed of 70% DMEM, 20% FBS and 10% DMSO. After the thawing of the 
frozen cells they were transferred into a vial containing 10 mL DMEM growth media and 
centrifugation at 1000 rpm for 5 minutes was done at room temperature. The growth media 
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was removed by aspiration and the cells were resuspended into a fresh growth media (15 mL) 
by pipetting up and down. The 15 mL cell suspension was then kept in a 37
0
C incubator at 
5% CO2. The cell density was monitored daily and was passaged on attainment of 95% 
confluence . 
4.2.2 Cellular internalization  
In a six-well culture plate MCF-7 breast cancer cells (1 × 10
5
/mL) were seeded and 
grown overnight. The wells were divided into four blocks i.e. each for control, TiO2 
nanoparticles, PCT and PCT-TiO2 nanocomposites and kept in incubator for 6 hours. By 
using a fluorescent microscope at λem - 515 nm and λex - 488 nm, the cells were examined. 
Furthermore, the cells were washed 3 times and resuspended in PBS. Analysis of drug uptake 
by the cells was observed by FACS Aria™ flow cytometer (BD Biosciences, San Jose, CA). 
4.2.3 Assay of anticancer activity 
The measure of the viability of the cells is done by MTT assay. It is a colorimetric 
assay that reduces to an insoluble, colored formazan product when it passes the mitochondria 
inside the cell. This reduction occurs only in metabolically active cells thus determining cell 
viability. In a 96-well plate the MCF-7 breast cancer cells (1 × 10
5
/mL) were seeded and 
incubated for 24 hours. Here too the wells were divided into four blocks i.e. each for control, 
TiO2 nanoparticles, PCT and PCT-TiO2 nanocomposites and further incubated for 48 hours. 
About 20 µl of MTT was added to each well, again incubated for 4 hours and relative 
anticancer activity was assessed. DMSO was added to solubilize the formazan crystal, and 
optical density at 595 nm was recorded.  
Cell viability (%) = Optical density (595 nm in test cells) / Optical density (595 nm in control cells) × 100 
4.2.4 DAPI staining 
The sample was equilibrated with PBS and the DAPI stock solution was diluted to 
300 nM in PBS and 300 µl of this dilute DAPI staining solution was added to the coverslip 
preparation so that all the cells are completely covered. After incubation for 5 minutes the 
sample was rinsed thrice with PBS. Excess buffer was removed from the coverslip, mounted 
and viewed under the fluorescence microscope. 
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4.2.5 Apoptosis through FACS 
To estimate the proportion of MCF-7 breast cancer cells in different phases of cell 
cycle affected by PCT, cellular DNA contents and apoptosis were measured by flow 
cytometry as described by Ormerod. 70% of ethanol in PBS was taken and this solution was 
put drop by drop on an approximately 1 x 10
6
cells/well and fixed gently. The whole system 
was kept in ice overnight. 40 pg/mL propidium iodide and 0.1 mg/mL RNAse were put in 
PBS and the cell sample solution was resuspended in it. At 37
0
C the cells were incubated for 
30 minutes and later analysis was carried out on flow cytometry (Becton-Dickinson, San 
Jose, CA, USA) that is equipped with an argon ion laser at 488 nm wavelength. Cell cycle 
study along with apoptosis analysis has been performed for determining the proportion of 
apoptotic cells.  
  
 
4.3 Results and Discussions 
4.3.1 Cell internalization study 
Flow cytometry has been employed to quantify the PCT uptake by MCF-7 breast 
cancer cells. As shown in figure 4.1, the time dependent uptake of PCT-TiO2 nanocomposites 
gradually increases with time. 
  
Figure 4.1: Quantification of PCT-TiO2 nanocomposite uptake by MCF-7 breast cancer cells 
by flow cytometry 
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After 2 hours the uptake of nanocomposite shows a logarithmic increase. Thereafter, a 
steady state increase has been found which does confirms an active uptake of PCT-TiO2 
nanocomposite in comparison to PCT alone which shows passive absorption by the cancer 
cells. The relative intracellular fluorescence intensity of PCT-TiO2 nanocomposite 
quantitatively increases at an order of 2 after 24 hours. Hence the efficacy of TiO2 
nanoparticles as a drug carrier has been confirmed and thereby it represents a promising 
approach in cancer therapy. 
 Similar results have been obtained in the study by Chen et al.
4
 where nearly 65% 
increase in fluorescence intensity has been obtained. However this study significantly differs 
from the results obtained by them. The reason may be a Ca
2+
 mediated mechanism where 
interaction between Ca
2+
 and TiO2 may physically and biochemically affect the 
internalization. The factors which affect this process are likely to be Ca-TiO2 complexation 
constant as well as low pH outside cancerous cells which favours the uptake of 
nanocomposite. 
4.3.2 Cytotoxicity study by MTT assay 
MTT assay is a very good indicator for understanding the extent of cancerous cell 
response to PCT-TiO2 nanocomposite. The assay was performed after 48 hours of cell 
culture. In case of control and treatment with TiO2 nanoparticles, cancerous cells show 
statistically no difference up to a concentration of 1 µg/mL. However, the cell viability of 
MCF-7 breast cancer cells treated by PCT and the nanocomposite shows drastic decrement. It 
is to be noted that PCT-TiO2 nanocomposite reduces the cell viability more than that of cells 
treated with PCT alone.   
 
Figure 4.2: Cytotoxicity effect of PCT and PCT-TiO2 nanocomposite on MCF-7 breast cancer 
cells by MTT assay 
 
Since TiO2 treated cells show a survivability of nearly or more than 95%, the non-
cytotoxicity of TiO2 nanoparticles at a concentration up to 1 µg/mL is assured. This lack of 
Titania Nanoparticles for the Intracellular Delivery of Paclitaxel in Breast Cancers 
 
 
32 
cytotoxicity is the key point for which we have employed this as a carrier for cancer therapy. 
Increasing concentration of PCT leads to increased lethality to cancerous cells suggesting a 
dose dependent effect in vitro. Furthermore, the increased cytotoxicity of the PCT-TiO2 
nanocomposite may be due to improved PCT cellular uptake which is supported by an 
induced release of the drug from nanocomposite within that microenvironment.  
The process of controlled release is an interesting phenomena for achieving PCT 
delivery loaded on TiO2 nanoparticle at normal physiological pH 7.4. It is assumed that most 
PCT remains in a conjugated form with TiO2 and thus serves as a carrier for an extended time 
period.  
Nanoparticle based drug delivery systems may be internalized through endocytic 
pathway
44
. The endocytosis is a pH dependent phenomena and the occurrence of low pH 
protonates the drug triggering the release of sorbed drug molecules and turning the surface 
charge of TiO2 nanoparticles to positive. This mechanism is further supported by the blocking 
of electrostatic interaction between PCT and TiO2 nanoparticles through Ca
2+
 which 
facilitates the drug release process. This above phenomena has been explained in detail 
previously. The faster release of the drug from PCT-TiO2 nanocomposites occurs after the 
entry of the carrier into the cancerous cell thereby significantly improving the cell killing rate 
and decreasing the side-effects of the drug i.e. destroying the immune system along with 
causing serious problems in the digestive tract. 
4.3.3 Apoptosis 
Cell deaths can be broadly divided into apoptosis and necrosis, the processes differing 
in their active participation of cells. The term apoptosis originates from the Greek word 
“falling off” of leaves from a tree, it is used to describe a phenomenon in which a cell 
actively participates in its own destructive processes. The signal transduction pathway leads 
to apoptosis and can be defined as an organized physiological mechanism for destroying 
injured and abnormal cells. This is an important part of cellular processes of cell cycle. There 
are several anticancer drugs like PCT which at optimal doses in vivo arrest the cancerous 
cells in their cell cycle.  
DAPI staining was performed to find out the improvement in anticancer activity of 
the pH responsive PCT-TiO2 nanocomposite. The apoptotic cells are morphologically 
characterized and evaluated. 
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Figure 4.3: Nuclear morphological changes in MCF-7 cells after different treatments for 48 
hours (a) untreated cells as control, (b) TiO2 nanoparticles, (c) PCT alone and (d) PCT-TiO2 
nanocomposite  
Morphological analysis shows convoluted nuclei with cavitation and fragmentation, 
with the formation of apoptotic bodies in MCF-7 breast cancer cell lines. We failed to 
observe the formation of apoptotic bodies with no treatment and also with TiO2 nanoparticles 
conduct. The amount of apoptotic bodies formed upon action with the PCT-TiO2 
nanocomposite is more than that of PCT treated alone. Moreover, we have observed the 
apoptotic cells treated with the nanocomposite without DAPI staining too. 
 
Figure 4.4: Morphological characterization of apoptosis(Without Dapi) in both the images 
(a) and (b) 
The apoptotic process is characterized with several morphological features i.e. loss of 
plasma membrane symmetry and its attachment, condensation of cytoplasm and nucleus, and 
internucleosomal cleavage of DNA. All these phenomena leads to formation of apoptotic 
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bodies which are rapidly eliminated by phagocytic cells without any inflammatory damage to 
surrounding cells.  
We used flow cytometry assay for cell cycle and apoptosis and it was concluded that 
PCT could interfere in cell cycle at G2/M phase, the data corresponding to the G2/M cycle 
arrest and thereby inducing apoptosis in MCF-7 cancer cell in dose and time dependent 
manner. However literature data supports that PCT could induce apoptosis through activation 
of caspase-3
45
.  
Pathways initiating apoptosis: Apoptosis results from two alternative pathways: one 
that is mediated by death receptors on cell surface (extrinsic pathway) and another caused due 
to changes in mitochondrial function (intrinsic pathway). Both the pathways are regulated by 
caspases. The extrinsic pathway involves the recruitment and activation of procaspase-8 by 
receptors containing the death domain located at the cell surfaces. Binding of procaspase-8 to 
death domain containing receptors results in apparent autocatalytic liberation of active 
caspase-8, which then activates procaspase-3. Consequently it has been proposed that the 
active caspase-8 cleaves Bid, generating a fragment that triggers intrinsic pathway. The 
intrinsic pathway is initiated by release of cytochrome C and other polypeptide from 
mitochondrial intermembrane space. This release involves the opening of a pore in 
mitochondrial membrane or translocation of Bcl-2 family membrane from the cytoplasm to 
mitochondrial membrane. Bax and Bak, in particular have been observed to translocate to 
mitochondria where they oligomerize to form pores and mediate cytochrome C release that 
accumulates in the cytoplasm where it binds to the scaffolding protein, Apaf-1, causing an 
ATP or dATP-dependent conformational change that allows Apaf-1 to bind procaspase-9. 
This interactivates caspase-9 which subsequently activates caspase-3. The effector caspases 
3, 6 and 7 when activated, cleave the key structural components of cytoskeleton and nucleus 
which results in characteristic morphology of apoptotic cells.  
However, this is the limitation of this study as the caspase-3 activity could not be 
investigated. 
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Figure 4.5: MCF-7 breast cancer cells (a) untreated (b) treated with TiO2 nanoparticles (c) 
with PCT alone and (d) with PCT-TiO2 nanocomposite, for 24 hours, washed and then 
harvested. The cells were fixed and stained with propidium iodide and the DNA content was 
analyzed by FACS 
 The figure 4.5 corresponds to the identification and quantification of apoptotic cells 
through DNA fragmentation. In control i.e. figure 4.5 (a), the cells are in active state of 
division spreading over G1, M and G2 phase with no apoptotic signal. The cells treated with 
TiO2 nanoparticles show minimum amount of apoptotic cells as in figure 4.5 (b). This may be 
due to mechanical rupturing of the membrane of cancerous cells. PCT treated cells, as in 
figure 4.5 (c), show a typical pattern of DNA content that reflect G0/G1-, S- and G2/M phase 
of cell cycle together with a sub G0/G1 phase corresponding to apoptotic cells by flow 
cytometry. This sub G0/G1 phase show significant increase for MCF-7 breast cancer cell lines 
upon treatment with the PCT-TiO2 nanocomposite as is clear from the figure 4.5 (d). This 
indicates the importance of the nanocomposite over PCT alone.  
Overall the MTT assay and FACS analysis of cell cycle shows increased apoptosis of 
cancerous cells in a concentration and time dependent manner. 
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The principle followed for apoptosis detection is fragmentation of DNA in 
correspondence with the cell cycle analysis via flow cytometry. This DNA fragmentation 
occurs at a later stage of apoptosis due to the activation of endonucleases during the apoptotic 
program. These nucleases degrade the higher order chromatin structure into 800 Kb 
fragments and subsequently into smaller DNA pieces. Flow cytometry allows simultaneous 
consideration of several parameters including size, granularity, and different fluorescent 
labelling of the same cells detect their pH change
46
. However, this method is non-specific, 
quick, simple to perform and applicable to all cell types.  
Endonucleases are more or less caspase activated DNAse
45
 resulting in DNA cleavage 
and generating broken DNA strands. Since the presence of broken DNA strands in not a 
unique feature of apoptosis, this assay should be followed by other methods to show 
specificity of measurement e.g. TUNEL assay. 
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CONCLUSION 
 
Nanoparticles are useful in improving the solubility of hydrophobic drugs, improving 
pharmacokinetics through sustained release after biodistribution, protecting sensitive drugs 
from low pH environment or enzymatic alterations and also most importantly providing 
targeted drug delivery for desired tissues. The use of functional nanocarriers like TiO2 
nanoparticles provide controlled intracellular delivery of drugs. Here, a functional pH 
responsive TiO2 nanoparticles are developed for intracellular delivery of PCT. The pH 
responsiveness of TiO2 nanoparticles occur because of two oxidation states i.e. TiO
- 
and 
TiOH
+ 
existing above and below pH 6.7 respectively. 
 Thereafter, the nanoparticles were evaluated for delivery of PCT in vitro to improve 
local therapy of breast cancer. TiO2 nanoparticles were synthesized via hydrothermal method 
and characterized. PCT was successfully encapsulated within the nanoparticles and it was 
found that the drug release at pH 5.2 is much higher than that at pH 7.4. The uptake of 
nanoparticles were observed using flow cytometry over MCF-7 breast cancer cell lines in 
vitro. The potency of PCT loaded nanoparticles was higher than that of the free drug 
demonstrating a synergistic effect.  
 The importance of the work lies in the increased bioavailability of drugs at the 
intended site of action with the development of PCT-TiO2 nanocomposite for intracellular 
delivery. Upon injection the nanoparticles remain stable as they encounter physiological pH 
7.4. Following the entry into the cells, protein pumps on the membrane of endosome causing 
the pH inside to drop to a value of pH 5.2. The drug release at this pH into the cytoplasm 
provides greater efficacy and reduced side effects.  
 Although the FDA approved drug, PCT is useful in treatment of cancer, this 
nanocomposite could be beneficial for other cancer types with variation in formulation. 
Broadening the reach of this PCT-TiO2 nanocomposite may be a key step in oncologic 
success. Continued investigation of functional TiO2 nanoparticles like the system described, 
will facilitate in the development of new material to meet the requirements for chemotherapy. 
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